Twist Bioscience Expects Q4 FY23 Revenue Guidance Of $63M-$64M, Compared To Previous Guidance Of $62M-$63M And Consensus Of $62.25M
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience has updated its Q4 FY23 revenue guidance to $63M-$64M, up from the previous guidance of $62M-$63M and above the consensus of $62.25M.
August 04, 2023 | 3:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Twist Bioscience's updated revenue guidance for Q4 FY23 is higher than previously expected, which could positively impact the company's stock price.
Twist Bioscience has raised its Q4 FY23 revenue guidance to a range that is higher than both its previous guidance and the consensus estimate. This indicates that the company expects to perform better than previously anticipated, which could lead to a positive reaction from the market and a potential increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100